JP6211767B2 - ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 - Google Patents

ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 Download PDF

Info

Publication number
JP6211767B2
JP6211767B2 JP2012528909A JP2012528909A JP6211767B2 JP 6211767 B2 JP6211767 B2 JP 6211767B2 JP 2012528909 A JP2012528909 A JP 2012528909A JP 2012528909 A JP2012528909 A JP 2012528909A JP 6211767 B2 JP6211767 B2 JP 6211767B2
Authority
JP
Japan
Prior art keywords
actriib
amino acid
fusion protein
seq
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012528909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504589A5 (OSRAM
JP2013504589A (ja
Inventor
ジャスバー シーラ，
ジャスバー シーラ，
ジョン ノフ，
ジョン ノフ，
ケン アティー，
ケン アティー，
Original Assignee
アクセルロン ファーマ， インコーポレイテッド
アクセルロン ファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ， インコーポレイテッド, アクセルロン ファーマ， インコーポレイテッド filed Critical アクセルロン ファーマ， インコーポレイテッド
Publication of JP2013504589A publication Critical patent/JP2013504589A/ja
Publication of JP2013504589A5 publication Critical patent/JP2013504589A5/ja
Application granted granted Critical
Publication of JP6211767B2 publication Critical patent/JP6211767B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012528909A 2009-09-09 2010-09-09 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 Active JP6211767B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27628709P 2009-09-09 2009-09-09
US61/276,287 2009-09-09
PCT/US2010/048322 WO2011031901A1 (en) 2009-09-09 2010-09-09 Actriib antagonists and dosing and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015027521A Division JP2015108012A (ja) 2009-09-09 2015-02-16 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用

Publications (3)

Publication Number Publication Date
JP2013504589A JP2013504589A (ja) 2013-02-07
JP2013504589A5 JP2013504589A5 (OSRAM) 2013-10-24
JP6211767B2 true JP6211767B2 (ja) 2017-10-11

Family

ID=43732801

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012528909A Active JP6211767B2 (ja) 2009-09-09 2010-09-09 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2015027521A Withdrawn JP2015108012A (ja) 2009-09-09 2015-02-16 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2016232363A Withdrawn JP2017048243A (ja) 2009-09-09 2016-11-30 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2017193336A Withdrawn JP2018002730A (ja) 2009-09-09 2017-10-03 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2018227174A Withdrawn JP2019055977A (ja) 2009-09-09 2018-12-04 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2020105837A Pending JP2020146070A (ja) 2009-09-09 2020-06-19 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015027521A Withdrawn JP2015108012A (ja) 2009-09-09 2015-02-16 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2016232363A Withdrawn JP2017048243A (ja) 2009-09-09 2016-11-30 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2017193336A Withdrawn JP2018002730A (ja) 2009-09-09 2017-10-03 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2018227174A Withdrawn JP2019055977A (ja) 2009-09-09 2018-12-04 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2020105837A Pending JP2020146070A (ja) 2009-09-09 2020-06-19 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用

Country Status (13)

Country Link
US (3) US20110070233A1 (OSRAM)
EP (3) EP3202459B1 (OSRAM)
JP (6) JP6211767B2 (OSRAM)
KR (4) KR20200086378A (OSRAM)
CN (1) CN102781518A (OSRAM)
AU (4) AU2010292203A1 (OSRAM)
BR (1) BR112012005225B8 (OSRAM)
CA (1) CA2773494A1 (OSRAM)
ES (2) ES2869580T3 (OSRAM)
IL (1) IL218502A0 (OSRAM)
IN (1) IN2012DN02766A (OSRAM)
MX (2) MX340451B (OSRAM)
WO (1) WO2011031901A1 (OSRAM)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314617B1 (en) 2004-07-23 2015-06-24 Acceleron Pharma Inc. ActRII receptor polypeptides
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX354099B (es) * 2007-02-01 2018-02-13 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TWI432449B (zh) 2007-02-02 2014-04-01 Acceleron Pharma Inc 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20160129095A (ko) 2007-02-09 2016-11-08 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
KR20220002710A (ko) * 2008-06-26 2022-01-06 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
PT2340031T (pt) 2008-08-14 2019-07-25 Acceleron Pharma Inc Armadilhas de gdf para uso no tratamento de anemia
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
WO2011056896A1 (en) * 2009-11-03 2011-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
WO2011063018A1 (en) * 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US20120121576A1 (en) 2010-11-08 2012-05-17 Jasbir Seehra Actriia binding agents and uses thereof
AU2012364736A1 (en) 2011-12-19 2014-07-24 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
AU2014209178B2 (en) 2013-01-25 2018-11-08 Takeda Pharmaceutical Company Limited Follistatin in treating Duchenne muscular dystrophy
EA201591423A1 (ru) 2013-02-01 2016-01-29 Санта Мария Биотерапевтикс, Инк. Введение антитела к активину-а пациентам
US20140220033A1 (en) * 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
KR102305109B1 (ko) * 2014-06-04 2021-09-27 악셀레론 파마 인코포레이티드 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
FI3227675T3 (fi) 2014-12-03 2023-05-25 Celgene Corp Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
CN107636154A (zh) 2015-03-26 2018-01-26 阿塞勒隆制药公司 促滤泡素抑制素相关的融合蛋白及其用途
RS61881B1 (sr) 2015-04-22 2021-06-30 Biogen Ma Inc Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića
EP3294320A4 (en) * 2015-05-13 2018-12-26 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
EP4190805A3 (en) 2015-05-20 2023-08-16 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
EP3420002A4 (en) * 2016-02-22 2020-01-15 Acceleron Pharma Inc. ACTRII ANTAGONISTS FOR USE TO INCREASE IMMUNITY
EP3426680B1 (en) 2016-03-10 2024-08-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
US11185569B2 (en) * 2016-05-04 2021-11-30 University Of Cincinnati ActRIIB:Fc to treat infertility in females
JP7280182B2 (ja) 2016-10-05 2023-05-23 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
JOP20190085A1 (ar) * 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
JP7051846B2 (ja) 2016-11-10 2022-04-11 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
JOP20190152A1 (ar) * 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
CA3098679A1 (en) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
MX2023005565A (es) * 2020-11-11 2024-02-23 Hq Han Antagonistas bifuncionales de activina/tgf-beta y rankl y usos de los mismos.

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5885794A (en) * 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US20050186593A1 (en) * 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6287816B1 (en) * 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US6692925B1 (en) * 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
JPH08505771A (ja) * 1993-01-12 1996-06-25 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−３
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) * 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) * 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5760010A (en) * 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
JPH11502717A (ja) 1995-04-11 1999-03-09 ザ ジェネラル ホスピタル コーポレーション 逆ツーハイブリッドシステム
EP0771873A3 (en) * 1995-10-27 1998-03-04 Takeda Chemical Industries, Ltd. Neuronal cell-specific receptor protein
US6605699B1 (en) * 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
CA2297489A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
CA2302525A1 (en) * 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
US6696411B1 (en) * 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
CN1317967A (zh) * 1998-09-17 2001-10-17 伊莱利利公司 蛋白质制剂
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6777205B1 (en) * 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
JP4487376B2 (ja) * 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
US6627424B1 (en) * 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
US6632180B1 (en) * 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
CA2445969A1 (en) 2001-04-30 2002-11-07 Cell Genesys, Inc. Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US6998118B2 (en) * 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
US7192717B2 (en) * 2002-02-21 2007-03-20 Wyeth GASP1: a follistatin domain containing protein
US8053552B2 (en) * 2002-04-18 2011-11-08 Mtm Laboratories, Ag Neopeptides and methods useful for detection and treatment of cancer
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) * 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
US20040197828A1 (en) * 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
RU2322261C2 (ru) * 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
EP2314617B1 (en) * 2004-07-23 2015-06-24 Acceleron Pharma Inc. ActRII receptor polypeptides
EP1824796A4 (en) 2004-11-16 2010-02-17 Avidia Res Inst PROTEIN SKELETONS AND USES THEREOF
US8128933B2 (en) * 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EA201692543A1 (ru) * 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US7361512B2 (en) * 2006-01-20 2008-04-22 Beckman Coulter, Inc. Low hemoglobin concentration cell percentage and method of use in detection of iron deficiency
WO2007120767A2 (en) * 2006-04-14 2007-10-25 Amgen Inc. Agonist erythropoietin receptor antibodies
EA200802213A1 (ru) * 2006-05-09 2009-10-30 Химекуэст Фармасьютикалз, Инк. Способы лечения заболеваний крови
ES2382993T3 (es) * 2006-07-21 2012-06-15 Lyne Laboratories, Inc. Composición líquida de acetato de calcio
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2124999B1 (en) * 2006-12-18 2012-10-03 Acceleron Pharma, Inc. Activin-actrii antagonists and uses for treating anemia
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
MX354099B (es) * 2007-02-01 2018-02-13 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TWI432449B (zh) * 2007-02-02 2014-04-01 Acceleron Pharma Inc 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20160129095A (ko) * 2007-02-09 2016-11-08 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
EP2150560A1 (en) * 2007-06-01 2010-02-10 Wyeth Methods and compositions for modulating bmp-10 activity
CA2699936A1 (en) * 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
KR20220002710A (ko) * 2008-06-26 2022-01-06 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PT2340031T (pt) * 2008-08-14 2019-07-25 Acceleron Pharma Inc Armadilhas de gdf para uso no tratamento de anemia
US8138142B2 (en) * 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
EP3275900A1 (en) * 2009-04-27 2018-01-31 Novartis AG Compositions and methods for increasing muscle growth
CN102482339B (zh) * 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) * 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
WO2011056896A1 (en) * 2009-11-03 2011-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
WO2011063018A1 (en) * 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
DK3875104T3 (da) * 2011-10-17 2025-02-03 Acceleron Pharma Inc Sammensætninger til behandling af ineffektiv erytropoiese
JP6298762B2 (ja) * 2012-07-02 2018-03-20 協和発酵キリン株式会社 抗ｂｍｐ９抗体を有効成分とする、腎性貧血、がん性貧血などの貧血に対する治療剤

Also Published As

Publication number Publication date
EP2475427A1 (en) 2012-07-18
MX2019006655A (es) 2019-09-09
MX340451B (es) 2016-07-08
US20180194828A1 (en) 2018-07-12
KR20120062874A (ko) 2012-06-14
US20210115105A1 (en) 2021-04-22
ES2869580T3 (es) 2021-10-25
KR20190047117A (ko) 2019-05-07
AU2020204176A1 (en) 2020-07-09
BR112012005225B1 (pt) 2022-04-19
CA2773494A1 (en) 2011-03-17
JP2020146070A (ja) 2020-09-17
IL218502A0 (en) 2012-07-31
EP2475427B1 (en) 2016-11-30
AU2016201712B2 (en) 2017-10-26
BR112012005225A2 (pt) 2020-09-01
ES2613523T3 (es) 2017-05-24
IN2012DN02766A (OSRAM) 2015-09-18
BR112012005225B8 (pt) 2023-01-10
MX2012003005A (es) 2012-06-12
JP2018002730A (ja) 2018-01-11
EP3919068A1 (en) 2021-12-08
US20110070233A1 (en) 2011-03-24
AU2010292203A1 (en) 2012-04-12
EP3202459A1 (en) 2017-08-09
AU2016201712A1 (en) 2016-04-07
WO2011031901A1 (en) 2011-03-17
KR20200086378A (ko) 2020-07-16
JP2019055977A (ja) 2019-04-11
EP2475427A4 (en) 2013-06-26
MX385217B (es) 2025-03-14
EP3202459B1 (en) 2021-04-14
JP2015108012A (ja) 2015-06-11
CN102781518A (zh) 2012-11-14
KR102133683B1 (ko) 2020-07-14
AU2018200463A1 (en) 2018-02-08
KR20210029836A (ko) 2021-03-16
AU2018200463B2 (en) 2020-07-09
JP2013504589A (ja) 2013-02-07
JP2017048243A (ja) 2017-03-09

Similar Documents

Publication Publication Date Title
JP6211767B2 (ja) ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP6662939B2 (ja) ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用
JP6195885B2 (ja) アクチビン−ＡｃｔＲＩＩａアンタゴニストおよび骨成長を促進するための使用
JP6132861B2 (ja) 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用
JP2009517051A5 (OSRAM)
HK40036911A (en) Variants derived from actriib and uses thereof
HK1227889A1 (en) Variants derived from actriib and uses therefor
HK1228413B (zh) 由actriib衍生的变体及其用途
HK1228411B (zh) 由actriib衍生的变体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141211

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160224

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170914

R150 Certificate of patent or registration of utility model

Ref document number: 6211767

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250